Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera Re-treatment in Rheumatoid Arthritis (Extension to ML19070)
NCT00502840Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Change From Baseline in DAS28 Score at 24 weeks. Started Jul 2007; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00502840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502840.